First oral SERD registered

A Menarini’s Orserdu has finally been registered on the ARTG, marking the first oral SERD in Australia with the company actively seeking reimbursement for breast cancer patients.

The TGA previously told Pharma in Focus that it had approved Orserdu, however it was yet to appear on the ARTG as the company had decided not to supply the medicine in Australia for the time being.

Orserdu is indicated for the treatment of postmenopausal women, and men, with ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.